Roche announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).
source https://www.pharmatutor.org/pharma-news/2020/roche-ocrevus-ocrelizumab-shorter-2-hour-infusion-time-approved-in-europe
No comments:
Post a Comment